In nonsecretory, oligo-secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti-MM agents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141730 | PMC |
| http://dx.doi.org/10.1002/ccr3.2636 | DOI Listing |
Publication Analysis
Top Keywords
multiple myeloma
8
serum free
4
free light
4
light chains
4
chains multiple
4
myeloma time
4
time extend
4
extend application?
4
application? nonsecretory
4
nonsecretory oligo-secretory
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!